COVID-19 Impact on Illumina, Inc.s Revenue and Operations (Medical Devices)

COVID-19 Impact on Illumina, Inc.s Revenue and Operations (Medical Devices)



Illumina, Inc. (Illumina) develops sequencing technologies used for the life science sciences, genomics, and molecular diagnostics. Illumina produces next generation sequencing (NGS) technologies, platforms, and reagents for research and clinical applications within medical genomics and molecular genetics. The report, COVID-19 Impact on Illumina, Inc.s Revenue and Operations (Medical Devices) presents a deep dive analysis into how Illumina, Inc. is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.

Deep dive analysis into how Illumina, Inc. is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.

Key Highlights

- The COVID-19 pandemic has caused many research labs to shut down or reduce capacity. This has resulted in a decreased demand for Illumina’s products and services and had a major impact on Illumina’s business performance. While Illumina announced stronger than expected revenue increases of 2% in Q1 2020 compared to Q1 2019, there was a decline in revenues of Q2 and Q3 2020, respectively, compared to the same time period in 2019.
- This was observed due to a significant drop in sales for sequencing instruments and services. However, Illumina’s business grew in the third quarter compared to second quarter of 2020 with growth in the sequencing consumables segment. The company announced its new SARS-CoV-2 Data Toolkit for researchers using next-generation sequencing (NGS) technology to study the virus. Illumina estimates lost revenues of approximately 20M USD as a result of the COVID-19 crisis.

Scope

The report provides a comprehensive analysis of the impact of COVID-19 on Illumina, Inc. -
- It provides insights on Illumina, Inc.s exposure to the regions and businesses impacted by the COVID-19 outbreak.
- It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.

Reasons to Buy

- An overview of how Illumina, Inc. will be affected by the COVID-19 pandemic.


COVID-19 impact analysis on Edwards Lifesciences Corp - Key Findings
Edwards Lifesciences Corp. Key Facts
Geographic spread analysis - COVID-19 vs Edwards Lifesciences Corp. sales
The impact of COVID-19 on regional GDP per capita levels
Edwards Lifesciences Corp. exposure: revenues by region and market vs regional impact levels
Edwards Lifesciences : revenue impact by region and market for 2020
Operational reactions from Edward Lifesciences? Indications from recruitment trends
Operational reactions from Edwards’ Indications from US pricing trends
Contact us


Reconstruction Meshes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)

Reconstruction Meshes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)Reconstruction Meshes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to

USD 7500 View Report

Disposable Endoscopes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)

Disposable Endoscopes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)Disposable Endoscopes (General Surgery) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to

USD 7500 View Report

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is

USD 1495 View Report

Global Peptide Therapeutics Market (2021 Edition) – Analysis By Drug Type (Generic, Innovative), Manufacturing Type (In-House, Outsourced), Application,, By Region, By Country: Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)

Executive The Global Peptide Therapeutics Market is valued at USD 32.1 Billion in the year 2020. The growth of Peptide Therapeutics is directly associated with drug development. New drug discovery

USD 2400 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available